Background: Previous studies have suggested that sexual dysfunction may be associated with posttraumatic stress disorder (PTSD). Yet such studies have not examined a full range of sexual functioning and have not accounted for the possibility that medication used to treat PTSD may contribute to sexual dysfunction. Objective: The current study compares the various components of sexual functioning among three groups of males: (1) untreated PTSD patients (n = 15), (2) PTSD patients currently treated with selective serotonin reuptake inhibitor (SSRI) agents (n = 27) and (3) a group of normal controls (n = 49). Methods: All participants completed an 18-item questionnaire for assessment of sexual functioning. Those with PTSD also completed the Impact of Events Scale and the Symptom Check List-90 (SCL-90). Results: Untreated and treated PTSD patients had significantly poorer sexual functioning in all domains (desire, arousal, orgasm, activity and satisfaction) as compared to normal controls. Those treated with SSRI had greater impairment in desire, arousal and frequency of sexual activity with a partner. There was a high correlation between sexual dysfunction among the PTSD group and the anger-hostility subscale of the SCL-90. Conclusions: PTSD appears to be associated with pervasive sexual dysfunction that is exacerbated by treatment with SSRIs. PTSD may represent a heterogeneous syndrome. Patients with PTSD have a high rate of comorbid panic disorder, major depression and anxiety, and it could thus be argued that these comorbid disorders, rather than PTSD, accounted for the observed result. Future research aimed at understanding comorbidity and heterogeneity should help to illuminate the psychobiology of PTSD and eventually guide both medication and psychosocial treatments.

1.
Kaplan HS: Anxiety and sexual dysfunction. J Clin Psychiatry 1988;49:21–25.
2.
Kaplan HS: Post-traumatic stress syndrome and sexual dysfunction. J Sex Marital Ther 1989;15:74–77.
3.
Letourneau EJ, Schewe PA, Frueh BC: Preliminary evaluation of sexual problems in combat veterans with PTSD. J Trauma Stress 1997;10:125–132.
4.
Fossey MD, Hamner MB: Clonazepam-related sexual dysfunction in male veterans with PTSD. Anxiety 1994;1:233–236.
5.
Harvey KV, Balon R: Clinical implications of antidepressant drug effects on sexual function. Ann Clin Psychiatry 1995;7:189–201.
6.
Gitlin MJ: Psychotropic medications and their effects on sexual function: Diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55:406–413.
7.
Lane RM: A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction: Incidence, possible etiology and implications for management. J Psychopharmacol 1997;11:72–82.
8.
Jacobsen FM: Fluoxetine-induced sexual dysfunction and an open trail of Yohimbin. J Clin Psychiatry 1992;53:119–122.
9.
Modell JG; Katholi CR, Modell JD, DePalma RL: Comparative sexual side effects of bupropin, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997;61:476–487.
10.
Aizenberg D, Zemishlany Z, Weizman A: Treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1998;18:320–324.
11.
Labbate LA, Grimes JB, Arana GW: Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders. Biol Psychiatry 1998;43:904–907.
12.
Schiavi RC, Schreiner-Engel P, Mandeli J, Schanzer H, Cohen E: Healthy aging and male sexual function. Am J Psychiatry 1990;147:766–771.
13.
Horowitz M, Wilner N, Alvarez W: Impact of Event Scale: A measure of subjective stress. Psychosom Med 1979;41:210–218.
14.
Swartzwald J, Solomon Z, Weisenberg M: Validation of the impact of Event Scale for psychological sequelae of combat. J Consult Clin Psychol 1987;55:251–256.
15.
Derogatis L, Clearly P: A confirmation of dimensional structure of the SCL-90: A study in construct validity. J Clin Psychiatry 1977;33:981–989.
16.
Derogatis L: The SCL-90 Manual Scoring, Administration, and Procedure for the SCL-90. Baltimore, John Hopkins University, School of Medicine, 1979.
17.
Solomon Z: Immediate and long-term effects of traumatic combat stress among Israeli veterans of the Lebanon war; in Wilson JP, Raphael B (eds): International Handbook of Traumatic Stress Syndromes. New York, Plenum Press, 1993, pp 321–332.
18.
Chemtob CM, Hamada RS, Roitblat HL, Muraoka M: Anger, anger control, and impulsivity in combat-related posttraumatic stress disorder. J Consult Clin Psychol 1994;62:827–832.
19.
Chemtob CM, Novaco RW, Hamada RS, Gross DM: Cognitive-behavioral treatment for severe anger in posttraumatic stress disorder. J Consult Clin Psychol 1997;65:184–189.
20.
Chemtob CM, Novaco RW, Hamada RS, Gross DM, Smith G: Anger regulation deficits in combat-related posttraumatic stress disorder. J Trauma Stress 1997;10:17–36.
21.
Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ: An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom 1998;67:328–331.
22.
Litz BT, Keane TM, Fisher L, Marx B, Monaco V: Physical health complaints in combat-related post-traumatic stress disorder: A preliminary report. J Traum Stress 1992;5:131–141.
23.
Solursh LP, Solursh DS: Male erectile disorders in Vietnam combat veterans with chronic post-traumatic stress disorder. Special issue: Sexuality and Disability in adolescence and beyond. Int J Adolesc Med Health 1994;7:119–124.
24.
Bozman AW, Beck JG: Covariation of sexual desire and sexual arousal: The effects of anger and anxiety. Arch Sex Behav 1991;20:47–60.
25.
Segraves RT: Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46:275–284.
26.
Herman JB, Brotman AW, Pollack MH, Falk WE, Biederman J, Rosenbaum JF: Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990;51:25–27.
27.
Waldinger MD, Olivier B: Selective serotonin reuptake inhibitor-induced sexual dysfunction: Clinical and research considerations. Int Clin Psychopharmacol 1998;13:S27–S33.
28.
Balon R: Sexual functioning with selective serotonin reuptake inhibitors. Am J Psychiatry 1999;156:807–808.
29.
Woolfolk RL, Grady DA: Combat-related posttraumatic stress disorder. Patterns of symptomatology in help-seeking Vietnam veterans. J Nerv Ment Dis 1988;176:107–111.
30.
Richman H: Personality disorder symptomatology among Vietnam veterans with combat-related PTSD. Anxiety 1996;2:286–295.
31.
Grimsley SR, Jann MW: Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930–957.
32.
Howell JR, Reynolds CF, Thase ME, Frank E, Jennings JR, Hounk PR, Berman S, Jacobs E, Kupfer DJ: Assessment of sexual function, interest and activity in depressed men. J Affect Disord 1987;13:61–66.
33.
Kinsey AC, Pomeroy WB, Martin CE: Sexual Behavior in the Human Male. Philadelphia, Saunders, 1948.
34.
Gerlock AA: Veterans’ responses to anger management intervention. Issues Ment Health Nurs 1994;15:393–408.
35.
Backham JC, Roodman AA, Barefoot JC, Haney TL, Helms MJ, Fairbank JA, Hertzberg MA, Kudler HS: Interpersonal and self-reported hostility among combat veterans with and without posttraumatic stress disorder. J Trauma Stress 1996;9:335–342.
36.
Schaller JL, Behar D: Sildenafil citrate for SSRI-induced sexual side effects. Am J Psychiatry 1999;156:156–157.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.